538. Clinical Evaluation of Drug-drug Interactions with Remdesivir

BACKGROUND: Remdesivir (RDV), a nucleotide prodrug approved for COVID-19, is a substrate and inhibitor of organic anion-transporter polyprotein (OATP) transporters and cytochrome P450 3A4 (CYP3A4) metabolizing enzyme based on in vitro data. Here, clinical studies of potential drug-drug interactions...

Descripción completa

Detalles Bibliográficos
Autores principales: Peng, Chi-Chi, Shelton, Mark, Raut, Anuja, Kwan, Anna, Chhabra, Kanika, Shen, Gong, Xiao, Deqing, Kim, Aryun, Madera, Sharline, Hyland, Robert H, Winter, Helen, Humeniuk, Rita
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678247/
http://dx.doi.org/10.1093/ofid/ofad500.607

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678247/
http://dx.doi.org/10.1093/ofid/ofad500.607

Ejemplares similares